BioSpace News Archive

TherapeuticsMD, Inc. today announced that the company will participate in three upcoming healthcare investor conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences.

Tandem Diabetes Care®, Inc. today announced it has been named a top workplace in San Diego by The San Diego Union-Tribune and awarded a “Future Forward” 2018 Top Workplaces honor.

The Antibody-Drug Conjugate community will join together for the 9th World ADC San Diego on November 12-15 at the Marriott Marquis San Diego with key influential researchers from around the world, to discuss clinical research experiences to help further the development of cancer therapeutics.

Prometic Life Sciences Inc. announced today that it will report its financial results for the third quarter ended September 30, 2018 on Wednesday November 14, 2018 after market close.

Oncopeptides AB (Nasdaq Stockholm: ONCO), a pharmaceutical company currently focused on developing novel treatments for multiple myeloma, announced today that the abstracts for the 60th American Society of Hematology (ASH) Annual Meeting (December 1-4, San Diego, California) have been released and include two melflufen presentations – one oral presentation (HORIZON) and one poster (ANCHOR).

Researchers with Biodesix® and Genentech, a member of the Roche Group, today presented findings on a test designed to predict response to atezolizumab (Tecentriq®) in patients with non-small cell lung cancer (NSCLC).

FUJIFILM Corporation (President: Kenji Sukeno) has announced the drug release mechanism of continuous action in tumors for the anti-cancer agent FF-10832, currently undergoing Phase I clinical trials in the United States.

In an all-time record year for FDA approvals (48 so far in 2018), Pharmapack Europe reports that innovation is also accelerating across the drug delivery and packaging industries.

Study Achieves Primary Endpoint, Demonstrating Statistically Significant LDL-C Reductions in Patients Receiving VK2809 at Week 12

Innovent Biologics, Inc. announced today that National Medical Products Administration (NMPA, successor to CFDA) has accepted its new drug application (NDA) for adalimumab biosimilar candidate (IBI303).